176 related articles for article (PubMed ID: 34806021)
1. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
Bauer M; Weyland A; Marx G; Bloos F; Weber S; Weiler N; Kluge S; Diers A; Simon TP; Lautenschläger I; Gründling M; Jaschinski U; Simon P; Nierhaus A; Moerer O; Reill L; Jörres A; Guo R; Loeffler M; Reinhart K; Riedemann N
Crit Care Explor; 2021 Nov; 3(11):e0577. PubMed ID: 34806021
[TBL] [Abstract][Full Text] [Related]
2. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Vlaar APJ; Witzenrath M; van Paassen P; Heunks LMA; Mourvillier B; de Bruin S; Lim EHT; Brouwer MC; Tuinman PR; Saraiva JFK; Marx G; Lobo SM; Boldo R; Simon-Campos JA; Cornet AD; Grebenyuk A; Engelbrecht JM; Mukansi M; Jorens PG; Zerbib R; Rückinger S; Pilz K; Guo R; van de Beek D; Riedemann NC;
Lancet Respir Med; 2022 Dec; 10(12):1137-1146. PubMed ID: 36087611
[TBL] [Abstract][Full Text] [Related]
3. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
Vlaar APJ; Lim EHT; de Bruin S; Rückinger S; Pilz K; Brouwer MC; Guo RF; Heunks LMA; Busch MH; van Paassen P; Riedemann NC; van de Beek D
Clin Transl Sci; 2022 Apr; 15(4):854-858. PubMed ID: 35029045
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients.
Lim EHT; Vlaar APJ; de Bruin S; Rückinger S; Thielert C; Habel M; Guo R; Burnett BP; Dickinson J; Brouwer MC; Riedemann NC; van de Beek D;
Intensive Care Med Exp; 2023 Jun; 11(1):37. PubMed ID: 37332066
[TBL] [Abstract][Full Text] [Related]
5. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
Vlaar APJ; de Bruin S; Busch M; Timmermans SAMEG; van Zeggeren IE; Koning R; Ter Horst L; Bulle EB; van Baarle FEHP; van de Poll MCG; Kemper EM; van der Horst ICC; Schultz MJ; Horn J; Paulus F; Bos LD; Wiersinga WJ; Witzenrath M; Rueckinger S; Pilz K; Brouwer MC; Guo RF; Heunks L; van Paassen P; Riedemann NC; van de Beek D
Lancet Rheumatol; 2020 Dec; 2(12):e764-e773. PubMed ID: 33015643
[TBL] [Abstract][Full Text] [Related]
6. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.
Lim EHT; Vlaar APJ; Bos LDJ; van Vught LA; Boer AMT; Dujardin RWG; Habel M; Xu Z; Brouwer MC; van de Beek D; de Bruin S;
Respir Res; 2022 Dec; 23(1):375. PubMed ID: 36566174
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults.
Chen G; Li N; Dai X; Tu S; Shen Z; Wu K; Jin T; Wu J; Peng C; Sheng G; Zhu M; Tang L; Li L
Infect Dis Ther; 2023 Feb; 12(2):663-675. PubMed ID: 36697937
[TBL] [Abstract][Full Text] [Related]
10. Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.
Laterre PF; Berry SM; Blemings A; Carlsen JE; François B; Graves T; Jacobsen K; Lewis RJ; Opal SM; Perner A; Pickkers P; Russell JA; Windeløv NA; Yealy DM; Asfar P; Bestle MH; Muller G; Bruel C; Brulé N; Decruyenaere J; Dive AM; Dugernier T; Krell K; Lefrant JY; Megarbane B; Mercier E; Mira JP; Quenot JP; Rasmussen BS; Thorsen-Meyer HC; Vander Laenen M; Vang ML; Vignon P; Vinatier I; Wichmann S; Wittebole X; Kjølbye AL; Angus DC;
JAMA; 2019 Oct; 322(15):1476-1485. PubMed ID: 31577035
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of vilobelimab for the treatment of COVID-19.
McCarthy MW
Expert Opin Biol Ther; 2023; 23(9):877-881. PubMed ID: 37421632
[TBL] [Abstract][Full Text] [Related]
12. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
Laterre PF; Pickkers P; Marx G; Wittebole X; Meziani F; Dugernier T; Huberlant V; Schuerholz T; François B; Lascarrou JB; Beishuizen A; Oueslati H; Contou D; Hoiting O; Lacherade JC; Chousterman B; Pottecher J; Bauer M; Godet T; Karakas M; Helms J; Bergmann A; Zimmermann J; Richter K; Hartmann O; Pars M; Mebazaa A;
Intensive Care Med; 2021 Nov; 47(11):1284-1294. PubMed ID: 34605947
[TBL] [Abstract][Full Text] [Related]
15. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
Cohen J; Carlet J
Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Sepsis Care Pathway 2019.
Labib A
Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
[No Abstract] [Full Text] [Related]
18. Selepressin, a novel selective vasopressin V
Russell JA; Vincent JL; Kjølbye AL; Olsson H; Blemings A; Spapen H; Carl P; Laterre PF; Grundemar L
Crit Care; 2017 Aug; 21(1):213. PubMed ID: 28807037
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.
Morris PE; Zeno B; Bernard AC; Huang X; Das S; Edeki T; Simonson SG; Bernard GR
Crit Care; 2012 Feb; 16(1):R31. PubMed ID: 22340283
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
